Brain: Plasma Aβ42/40 and phosphorylated-tau217 help predict the pathological prognosis of Alzheimer's disease

More and more people realize that the pathophysiology of Alzheimer’s disease is a highly complex and dynamic process, starting with the early accumulation of amyloid-β, followed by tau deposition and neurodegeneration.
These pathological changes can be passed Cerebrospinal fluid analysis, PET and MRI detection
.

However, although these techniques are clinically useful, they are invasive, expensive or time-consuming, which limits their use in clinical practice or their availability in the same person.

More and more people realize that the pathophysiology of Alzheimer’s disease is a highly complex and dynamic process, starting with the early accumulation of amyloid-β, followed by tau deposition and neurodegeneration.

Joana B Pereira et al.

The study measured the plasma amyloid-β 42/40 (a β42 /40), phosphorylated tau181, phosphorylated tau217 and neurofilament light chain
.

All subjects underwent longitudinal amyloid ( ¹⁸ F-flutemamol) and tau ( ¹⁸ F-RO948) PET, structural MRI (T1-weighted) and cognitive tests

^{18 18}

Univariate linear mixed-effects models show that there are several significant associations between plasma biomarkers and imaging and cognitive measures
.

However, when all biomarkers were included in the same multivariate linear mixed effects model, low baseline plasma Aβ42/40 independently predicted an increase in longitudinal amyloid-PET signal (P = 0.

Low baseline plasma Aβ42/40 independently predicted an increase in longitudinal amyloid-PET signal (P = 0.

Plasma Aβ42/40 levels independently predict longitudinal amyloid-PET deposition in non-dementia individuals
.

Plasma Aβ42/40 levels independently predict longitudinal amyloid-PET deposition in non-dementia individuals
.

With the increase of tau-PET signal, high plasma phosphorylated tau217 can independently predict brain atrophy and cognitive deterioration (P<0.
004)
.

The increase of tau-PET signal and high plasma phosphorylated tau217 can independently predict brain atrophy and cognitive deterioration (P<0.
004)
.

Plasma P-tau217 levels independently predict the longitudinal accumulation of tau in non-dementia individuals
.

Plasma P-tau217 levels independently predict the longitudinal accumulation of tau in non-dementia individuals
.

The performance of these biomarkers is as good or better than the corresponding biomarkers detected in the cerebrospinal fluid
.

In addition, they exhibit similar performance to binary plasma biomarker values ​​defined using Youden Index, which is easier to achieve in the clinic
.

In addition, the study found that plasma Aβ42/40 and phosphorylated-tau217 could not predict the longitudinal changes in patients with non-Alzheimer's neurodegenerative diseases

In summary, baseline plasma Aβ42/40 and P-tau217 levels are independent predictors of pathological changes that occur in the course of Alzheimer's disease
.

Plasma Aβ42/40 and P-tau217 can be used as important prognostic tools for evaluating disease progression in clinical practice, so as to achieve more accurate patient management and better disease monitoring in future clinical trials

Baseline plasma Aβ42/40 and P-tau217 levels are independent predictors of pathological changes that occur in the course of Alzheimer's disease
.
Plasma Aβ42/40 and P-tau217 can be used as important prognostic tools for evaluating disease progression in clinical practice, so as to achieve more accurate patient management and better disease monitoring in future clinical trials
.
Baseline plasma Aβ42/40 and P-tau217 levels are independent predictors of pathological changes that occur in the course of Alzheimer's disease
.
Plasma Aβ42/40 and P-tau217 can be used as important prognostic tools for evaluating disease progression in clinical practice, so as to achieve more accurate patient management and better disease monitoring in future clinical trials
.
manage

Original source

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects, Brain, Volume 144, Issue 9, September 2021, Pages 2826 –2836, https://doi.
org/10.
1093/brain/awab163

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects, Brain, Volume 144, Issue 9, September 2021, Pages 2826 –2836, https://doi.
org/10.
1093/brain/awab163 Plasma markers predict in amyloid Changes, of tau, atrophy and Cognition in non-DEMENTED Subjects, Brain, Volume 144, Issue.
9, September 2021, Pages 2826 -2836, https://doi.
org/10.
1093/brain/awab163 in this message